Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
Treatment for Subjects With Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2009-07-20
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117897
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 524
- Registration Number
- NCT00118209
- Locations
- 🇺🇸
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸Charles R. Wood Cancer Center at Glens Falls Hospital, Glens Falls, New York, United States
🇺🇸Madigan Army Medical Center - Tacoma, Tacoma, Washington, United States
A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2005-07-07
- Last Posted Date
- 2008-05-16
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117455
Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors
- First Posted Date
- 2005-06-22
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 309
- Registration Number
- NCT00115128
Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)
- First Posted Date
- 2005-06-20
- Last Posted Date
- 2008-10-31
- Lead Sponsor
- Amgen
- Target Recruit Count
- 84
- Registration Number
- NCT00114764
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)
- Conditions
- Interventions
- First Posted Date
- 2004-11-10
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 30
- Registration Number
- NCT00096460
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer
- Conditions
- First Posted Date
- 2004-06-21
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT00005993
DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse
- Conditions
- First Posted Date
- 2004-05-28
- Last Posted Date
- 2010-07-02
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 180
- Registration Number
- NCT00083681
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
- First Posted Date
- 2004-05-27
- Last Posted Date
- 2015-11-23
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 668
- Registration Number
- NCT00083551
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT00005986
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.